Ken Griffin Vaccinex, Inc. Transaction History

Citadel Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.34 - $0.48 $23,307 - $32,904	68,551 Added 198.51%	103,084 $37,000
Q1 2023 May 15, 2023	BUY	$0.39 - $0.65 $10,508 - $17,514	26,945 Added 355.1%	34,533 $13,000
Q4 2022 Feb 14, 2023	SELL	$0.44 - $131.17 $40,779 - $12.2 Million	-92,680 Reduced 92.43%	7,588 $4,000
Q3 2022 Nov 14, 2022	BUY	$0.48 - $109.22 $20,334 - $4.63 Million	42,364 Added 73.16%	100,268 $50,000
Q2 2022 Aug 15, 2022	SELL	$1.05 - $1.39 $10,357 - $13,710	-9,864 Reduced 14.56%	57,904 $63,000
Q1 2022 May 16, 2022	SELL	$0.92 - $1.94 $12,563 - $26,492	-13,656 Reduced 16.77%	67,768 $90,000
Q4 2021 Feb 14, 2022	BUY	$1.04 - $2.12 $68,565 - $139,767	65,928 Added 425.45%	81,424 $84,000
Q2 2021 Aug 16, 2021	SELL	$2.01 - $3.0 $97,119 - $144,954	-48,318 Reduced 75.72%	15,496 $43,000
Q1 2021 May 17, 2021	BUY	$2.09 - $5.11 $60,024 - $146,759	28,720 Added 81.84%	63,814 $190,000
Q4 2020 Feb 16, 2021	SELL	$1.66 - $2.35 $18,186 - $25,746	-10,956 Reduced 23.79%	35,094 $73,000
Q3 2020 Nov 16, 2020	BUY	$1.75 - $8.19 $80,587 - $377,149	46,050 New	46,050 $82,000

426K

Ticker VCNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,664,100
Market Cap $240M
Description
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab,...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.